Dariusz Pawlak

Dariusz Pawlak

Auto-generated profile, based on publicly available information

Dariusz Pawlak

Radioisotope Centre Polatom, National Centre for Nuclear Research, Otwock, Poland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
JKJolanta Kunikowska
Jolanta Kunikowska
LKLeszek Królicki
Leszek Królicki
AHAlicja Hubalewska-Dydejczyk
Alicja Hubalewska-Dydejczyk
RMRenata Mikołajczak
Renata Mikołajczak
ASAnna Sowa-Staszczak
Anna Sowa-Staszczak
DPDariusz Pawlak
Dariusz Pawlak
Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy 90Y beta emitter for larger lesions and the lower energy 177Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined 90Y/177Lu-DOTATATE therapy in comparison to 90Y-DOTATATE alone. Methods Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n = 25) was treated with 90Y-DOTATATE, whereas group B (n = 25) received the 1:1 90Y/177Lu-DOTATATE. The administered activity was based on 3.7 GBq/m2 body surface area in three to five cycles, with amino acid infusion for nephroprotection. Results The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p = 0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p > 0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. Conclusion The results indicate that therapy with tandem radioisotopes (90Y/177Lu-DOTATATE) provides longer overall survival than with a single radioisotope (90Y-DOTATATE) and the safety of both methods is comparable.

15 October 2009 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JĆJarosław Ćwikła
Jarosław Ćwikła
ASA. Sankowski
A. Sankowski
NSN. Seklecka
N. Seklecka
JBJ. R. Buscombe
J. R. Buscombe
ANA. Nasierowska-Guttmejer
A. Nasierowska-Guttmejer
JWJ. Walecki
J. Walecki
Background: To evaluate the clinical and radiological effectiveness of [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) Y-90 in patients with extensive progressive gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs). Materials and methods: Sixty patients with histologically proven GEP-NETs were treated with DOTATATE Y-90. Clinical responses were assessed 6 weeks after completing therapy and then after each of the 3- to 6-month intervals. The radiological response was classified according to RECIST criteria. Results: At 6 months after final treatment, radiological partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was observed in 13 patients (23%), and the remaining patients had stable disease (SD; less than 30% decrease in the sum of the longest diameter of target lesions or less than 20% increase in the sum of the longest diameter of target lesions) (77%). Clinical PR at 6 months was in 43 patients (72%), nine patients had SD and progressive disease (PD) was noted in eight patients. Median progression-free survival (PFS) was 17 months, while the median overall survival (OS) was 22 months. In eight patients with early PD, the PFS was 4.5 and OS 9.5 months, while in those with SD or PR, PFS and OS were 19.5 and 23.5 months, respectively. After 12 months of follow-up, five patients had World Health Organization (WHO) grade 2 or 3 renal toxicity. Haematological toxicity (WHO grade 3 and 4) was noted during therapy in 10% of patients and persisted in 5%. Conclusions: DOTATATE Y-90 therapy is effective and relatively safe in patients with GEP-NET. Standard doses of DOTATATE Y-90 result in a relatively low risk of myelotoxicity. However, due to ongoing risk of renal toxicity, careful monitoring of the kidney is recommended.

29 November 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LKLeszek Królicki
Leszek Królicki
FBFrank Bruchertseifer
Frank Bruchertseifer
JKJolanta Kunikowska
Jolanta Kunikowska
HKHenryk Koziara
Henryk Koziara
BKBartosz Królicki
Bartosz Królicki
AMAlfred Morgenstern
Alfred Morgenstern

30 April 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
LKLeszek Królicki
Leszek Królicki
FBFrank Bruchertseifer
Frank Bruchertseifer
JKJolanta Kunikowska
Jolanta Kunikowska
HKHenryk Koziara
Henryk Koziara
BKBartosz Królicki
Bartosz Królicki
AMAlfred Morgenstern
Alfred Morgenstern
Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha emitters, e.g. 213Bi, that deposit their high energy within a short range allow the selective irradiation of tumor cells while sparing adjacent neuronal structures.

11 May 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ASAnna Sowa-Staszczak
Anna Sowa-Staszczak
DPDorota Pach
Dorota Pach
RCRobert Chrzan
Robert Chrzan
MTMałgorzata Trofimiuk
Małgorzata Trofimiuk
ASAgnieszka Stefańska
Agnieszka Stefańska
Alicja Hubalewska-DydejczykAlicja Hubalewska-Dydejczyk
Alicja Hubalewska-Dydejczyk
Purpose Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms of diffuse neuroendocrine cells. Surgery is the main aim in the treatment of NETs, which becomes impossible in the case of large tumours or infiltration into other tissues and/or important blood vessels. Neoadjuvant therapy might be helpful in decreasing NET size also, leading us to the point where a tumour, previously considered inoperable, becomes operable. The aim of the study was to assess the usage of peptide receptor radionuclide therapy (PRRT) as a neoadjuvant treatment, enabling surgical intervention in primary inoperable NET. Methods Among 47 patients treated with PRRT, 6 patients were chosen with large, inoperable tumours, for whom enabling of complete surgical excision of the lesions might offer the prospect for a cure. Response to the therapy was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST). Results The mean tumour size decreased from 6.9 (min. 3.1 cm, max. 9.6 cm) before therapy to 5.4 cm (min. 3.1 cm, max. 9.5 cm) after the treatment. According to RECIST, stabilization of the disease was observed in four and partial responses in two patients. In two patients, reduction of the tumour size enabled surgical intervention. Conclusion (1) PRRT might be considered a neoadjuvant therapy in primary inoperable NETs. (2) According to RECIST, stabilization of the disease was observed in the majority of patients. (3) We suggest that not only tumour diameter changes, but also tumour volume and contrast enhancement changes in computed tomography should be taken into consideration in assessment of the response to the therapy. (4) Somatostatin receptor scintigraphy is an important tool for qualification of the radioisotope therapy and also for the assessment of the response to PRRT.

18 March 2017 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JKJolanta Kunikowska
Jolanta Kunikowska
DPDariusz Pawlak
Dariusz Pawlak
MBMarianna I. Bąk
Marianna I. Bąk
BKBeata Kos-Kudła
Beata Kos-Kudła
RMRenata Mikołajczak
Renata Mikołajczak
LKLeszek Królicki
Leszek Królicki